Host: Mario R. Nacinovich, Jr., MSc <br>

Guest: Jonathan Riess, MD, MS <br>


  <p>Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center. </p>

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Comparing Combination Therapies for Lung Cancer: Rationales & Risks

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by

Medicine

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;Sponsored by

Share Comparing Combination Therapies for Lung Cancer: Rationales & Risks

Sign up to save your podcasts

Comparing Combination Therapies for Lung Cancer: Rationales & Risks

Comparing Combination Therapies for Lung Cancer: Rationales & Risks